Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma - Takeaways - MDSpire

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma

  • By

  • Meera Mohan

  • Aniko Szabo

  • Heloise Cheruvalath

  • Anna Clennon

  • Vineel Bhatlapenumarthi

  • Anannya Patwari

  • Metodi Balev

  • Divaya Bhutani

  • Asis Shrestha

  • Sharmilan Thanendrarajan

  • Binod Dhakal

  • Maurizio Zangari

  • Anup Trikannad

  • Sruthi Vellanki

  • Samer Al-Hadidi

  • Suzanne Lentzsch

  • Frits van Rhee

  • Aishee Bag

  • Anita D’Souza

  • Nishi Shah

  • Rajshekhar Chakraborty

  • Mansi R. Shah

  • Carolina Schinke

  • April 23, 2025

  • 0 min

Share

  • 1

    BCMA-targeting bispecific antibodies for multiple myeloma are effective but increase the risk of serious infections and infection-related mortality.

  • 2

    Intravenous immunoglobulin (IVIG) supplementation may mitigate infection risk, but data supporting its effectiveness in BCMA-directed therapies is limited.

  • 3

    The study analyzed 225 patients treated with BCMA-directed bispecific antibodies, with 41% receiving primary IVIG prophylaxis.

  • 4

    Infection-free survival, overall survival, and progression-free survival were evaluated using statistical methods adjusted for immortal-time bias.

  • 5

    Consensus recommendations for IVIG use in BCMA therapy vary, with some advocating for primary prophylaxis and others for response-based initiation.

Original Source(s)

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma

  • by Meera Mohan, Aniko Szabo, Heloise Cheruvalath, Anna Clennon, Vineel Bhatlapenumarthi, Anannya Patwari, Metodi Balev, Divaya Bhutani, Asis Shrestha, Sharmilan Thanendrarajan, Binod Dhakal, Maurizio Zangari, Anup Trikannad, Sruthi Vellanki, Samer Al-Hadidi, Suzanne Lentzsch, Frits van Rhee, Aishee Bag, Anita D’Souza, Nishi Shah, Rajshekhar Chakraborty, Mansi R. Shah, Carolina Schinke

  • April 23, 2025

Related Content

Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies

CRISPR Enables In Vivo CAR T Cell Production

In vivo gene editing strategy generates CAR T cells directly inside the body – sidestepping costly manufacturing

  • March 30, 2026

  • 2 min
Infection risk associated with teclistamab in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence